Avid Bioservices Inc (CDMO)

[keep_trying]

Bio, your logic sequence for Halozyme order impacts makes sense. I recall CJ or someone else on this message board had flagged last year how Avid may be picking up some primary production for trials that had been getting supplied by Cook, due to Halozyme encountering quality and delivery problems. If problems of that sort were real (my memory being fuzzy on this) and they got resolved or a shift to Avid is taking more time, that can explain why PPHM has slowed down their Avid production capacity expansion plans to give customer orders time to create a "pull" for expansions again and why revenues plateaued. On context here is that the Avid sales growth backing off is just a glitch to be resolved soon and the other is a signal that Avid needs to find new customers (beyond Halozyme growth) to support PPHM self funding business plan goal delivery.

Another point is that Avid may be somewhat obligated or compelled to preserve production capacity for use by Halozyme rather than subscribing new customers for that capacity, but PPHM has provided for capacity expansion that can cover both needs, once a customer is indicating commitments to orders.

As I noted in my post to GJH, the science and business relationships are getting complex to keep current on.

Best wishes and IMO.
KT